Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
